Integrated Evaluation of Survival, Surgical Conversion, and Toxicity for Induction Therapy in Initially Unresectable Colorectal Liver Metastases: An Individual Patient Data Network Meta-analysis.
Chemotherapy with bevacizumab helped convert initially inoperable liver metastases to resectable tumors, offering surgery options.
Patients with initially unresectable colorectal cancer liver metastases (CRLM) could derive benefits from active induction regimens by increasing the likelihood of surgical conversion. Bevacizumab plus doublet chemotherapy showed the most favorable benefit-risk balance and may represent an optimal compromise for patients with initially unresectable CRLM.
What the study was
- Study design
- Randomized controlled trial
- Population
- Cancer/disease patients
- Sample size
- 1368
- Category
- Drug Development
- Maturity
- Potentially Practice-Changing
- Journal
- Annals of surgical oncology
Why it surfaced
Matched topic(s): Novel therapeutics: immunotherapy, CAR-T, targeted therapy. Study design: Randomized controlled trial. Score 7/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.